Yahoo
NasdaqCM - Delayed Quote USD

Envoy Medical, Inc. (COCH)

6.63 +0.13 (+2.00%)
At close: October 30 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for COCH
  • Previous Close 6.50
  • Open 6.28
  • Bid 0.69 x 400
  • Ask 6.86 x 100
  • Day's Range 6.26 - 6.70
  • 52 Week Range 3.63 - 9.54
  • Volume 48,364
  • Avg. Volume 12,511
  • Market Cap (intraday) 51.313M
  • Beta (5Y Monthly) 1.95
  • PE Ratio (TTM) --
  • EPS (TTM) -7.60
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 21.67
  • Zacks Rating Neutral

Envoy Medical, Inc., a hearing health company, provides medical technologies across the hearing loss spectrum. The company's medical technologies are designed to shift the paradigm within the hearing industry and bring providers and patients the hearing devices desire. It offers personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.

www.envoymedical.com

43

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

COCH
0.30%
S&P 500 (^GSPC)
10.73%

1-Year Return

COCH
11.48%
S&P 500 (^GSPC)
11.11%

3-Year Return

COCH
44.75%
S&P 500 (^GSPC)
81.91%

5-Year Return

COCH
93.19%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 51k
Earnings -7.27M
Profit Margin -14,258.82%

Q2

FY25

Q3

FY25

Q1

FY26

Q2

FY26

-6M
-4M
-2M
0
-18000.0%
-16000.0%
-14000.0%
-12000.0%
-10000.0%

Analyst Insights

View More

Analyst Price Targets

20.00
21.67 Average
6.63 Current
25.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/27/2026
Analyst Lake Street
Rating Action Maintains
Rating Buy
Price Action Adjusts
Price Target 2.5 -> 25

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -86.53%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    207k

  • Net Income Avi to Common (ttm)

    -28.46M

  • Diluted EPS (ttm)

    -7.60

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    19.68M

  • Total Debt/Equity (mrq)

    21.93%

  • Levered Free Cash Flow (ttm)

    -8.22M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: